Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

J Assist Reprod Genet. 2010 Aug;27(8):449-56. doi: 10.1007/s10815-010-9427-2. Epub 2010 May 14.

Abstract

Purpose: To evaluate the role of Anti-mullerian hormone (AMH) in predicting cumulative pregnancy outcome during in-vitro fertilization (IVF) treatment.

Methods: Serum AMH levels on day 6 of ovarian stimulation were taken from 180 women undergoing IVF with or without intracytoplasmic sperm injection (ICSI). The main outcome measures were ongoing pregnancy in the fresh cycle, cumulative ongoing pregnancy and ovarian response.

Results: There was a trend of higher median AMH levels in subjects achieving ongoing pregnancy in the fresh IVF cycle. The median AMH levels were significantly higher in subjects attaining ongoing pregnancy cumulatively and in subjects showing ovarian hyper-response in the stimulated cycle. Areas under the ROC curves were 0.606 and 0.792 for the prediction of cumulative ongoing pregnancy and ovarian hyper-response respectively.

Conclusions: Serum AMH concentration on day 6 of stimulation was significantly higher in subjects who achieved cumulative ongoing pregnancy in IVF compared to those who did not. Serum AMH is a reasonably good predictor of ovarian hyper-response.

MeSH terms

  • Adult
  • Anti-Mullerian Hormone / blood*
  • Female
  • Fertilization in Vitro*
  • Humans
  • Pregnancy
  • Pregnancy Rate
  • Retrospective Studies

Substances

  • Anti-Mullerian Hormone